Search

Displaying results 3001 - 3010 of 10000 in total
  1. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. … The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]

  2. Drug

    Sulfacytine

    go.drugbank.com/drugs/DB01298
    Approved

    Sulfacytine is a short-acting sulfonamide. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. … However, many strains of an individual species may be resistant.

    Synonyms: 1-ethyl-N-sulfanilylcytosine
  3. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers … These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as

  4. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    [L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was … multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.

  5. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    efficacy, especially in patients that respond poorly to anti-VEGF-A monotherapy. … target VEGF-A.

  6. Drug

    Fexapotide

    go.drugbank.com/drugs/DB05493
    Investigational

    NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.

    Categories: Drugs Used in Benign Prostatic Hypertrophy
  7. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    This rare congenital autosomal recessive disorder of pyrimidine metabolism is caused by a defect in uridine monophosphate synthase (UMPS), a bifunctional enzyme that catalyzes the final two steps of the … By pre-administering with uridine (as the prodrug uridine triacetate), higher doses of 5-FU can be given allowing for improved efficacy and a reduction in toxic side effects [A18578].

  8. Drug

    Ingenol mebutate

    go.drugbank.com/drugs/DB05013
    ApprovedWithdrawn

    PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions … Before approval, ingenol mebutate was called PEP005 as an investigational drug.

  9. Drug

    Agalsidase beta

    go.drugbank.com/drugs/DB00103
    ApprovedInvestigational

    [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa].

  10. Drug

    Ecabet

    go.drugbank.com/drugs/DB05265
    Investigational

    Ecabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis. … Ecabet is a prescription eye drop for the treatment of dry eye syndrome.

    Categories: Compounds used in a research, industrial, or household setting, Pepsin A, antagonists & inhibitors